Delcath Systems Secures $16.3 Million in New Funding
Delcath Systems, Inc. (Nasdaq: DCTH) is making notable strides in the interventional oncology space. The company has recently exercised Series E and E1 warrants, effectively raising $16.3 million. This substantial funding boosts their ongoing development initiatives and commercial efforts aimed at tackling liver cancers. The warrant exercise represents a proactive step for Delcath, highlighting the company's commitment to enhancing treatment options for its patients.
Strengthening Financial Position for Growth
As part of its fundraising, Delcath saw approximately 6.6% of the exercised warrants engage in cashless exercise provisions. Originally issued during a private placement in July and August 2019, the warrants had an exercise price set at $10.00 per share and will remain valid until late 2024. With this influx of capital, Delcath aims to leverage its current cash reserves and anticipated operational revenue to bolster growth.
CEO's Vision for Future Developments
Gerard Michel, CEO of Delcath Systems, expressed optimism regarding the company’s financial health. He noted, “With the exercise of these warrants and our increasing cash flow from revenue growth, we believe we are well-positioned to further our commercialization objectives and enhance clinical development plans.” He emphasized the critical role of their drug HEPZATO in treating patients with uveal melanoma, pointedly discussing the potential for new clinical trials and investments.
Innovative Treatment Solutions
Delcath Systems is renowned for its innovative approaches in oncology, primarily through its proprietary products, HEPZATO KIT and CHEMOSAT. These systems are engineered to administer concentrated doses of chemotherapy directly to the liver while minimizing systemic exposure and side effects. This targeted approach not only improves the efficacy of treatment but also safeguards patients' overall health during the procedure.
HEPZATO KIT: A Breakthrough in Oncology
The HEPZATO KIT is recognized within the United States as a combination drug and device product. It has received regulatory approval from the FDA, allowing it to be marketed for specific cancer treatments. The system utilizes a specialized device that isolates hepatic venous blood, ensuring high local drug concentration while limiting systemic exposure. This technology supports the effective delivery of melphalan, a chemotherapeutic agent, allowing for significant tumor responses.
International Approvals and Expanding Reach
In Europe, the device-only variant of this technology, known as CHEMOSAT, has been classified as a Class III medical device. Its approval further expands Delcath's capabilities, enabling physicians to conduct percutaneous hepatic perfusion procedures for various liver cancers. The recognition of these products across multiple regions showcases the importance of Delcath's innovations in global oncology therapy.
Commitment to Patient-Centric Solutions
Delcath Systems maintains a steadfast commitment to improving patient outcomes in liver cancer treatment. By adequately addressing the challenges associated with traditional chemotherapy, Delcath is poised to enhance the quality of care for patients battling these challenging conditions. Their ongoing dedication to clinical research and product development signifies a bright future for liver cancer treatment.
Frequently Asked Questions
What is Delcath Systems focusing on with the new funding?
Delcath Systems is utilizing the $16.3 million funding to support commercialization efforts and further advance clinical trials for its core products, particularly HEPZATO.
How does HEPZATO KIT work?
HEPZATO KIT delivers high-dose chemotherapy directly to the liver, aiming to destroy cancer cells while minimizing harmful side effects to the rest of the body.
What are the key products of Delcath Systems?
The key products include HEPZATO KIT and CHEMOSAT, both designed for targeted liver cancer treatment through innovative interventional oncology techniques.
Is HEPZATO KIT approved for use outside the United States?
Yes, the device-only configuration CHEMOSAT is approved in Europe as a Class III medical device.
What is the future outlook for Delcath Systems?
With recent funding and strong demand for its products, Delcath Systems is well-positioned to advance its clinical trials and expand its market presence in oncology.
